Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of JS207 combination therapy for recurrent or metastatic triple-negative breast cancer
CTR20252482Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JS207, bulumtatug fuvedotin in triple-negative breast cancer (TNBC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
JS207bulumtatug fuvedotin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20252482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252482.